APASL HCV guidelines of virus-eradicated patients by DAA on how to monitor HCC occurrence and HBV reactivation
Tatsuo Kanda,George K. K. Lau,Lai Wei,Mitsuhiko Moriyama,Ming-Lung Yu,Wang-Long Chuang,Alaaeldin Ibrahim,Cosmas Rinaldi Adithya Lesmana,Jose Sollano,Manoj Kumar,Ankur Jindal,Barjesh Chander Sharma,Saeed S. Hamid,A. Kadir Dokmeci,Mamun-Al-Mahtab,Geoffrey W. McCaughan,Jafri Wasim,Darrell H. G. Crawford,Jia-Horng Kao,Yoshihiko Ooka,Osamu Yokosuka,Shiv Kumar Sarin,Masao Omata
DOI: https://doi.org/10.1007/s12072-019-09988-7
IF: 9.029
2019-01-01
Hepatology International
Abstract:In the direct-acting antiviral (DAA) era for hepatitis C virus (HCV) infection, sustained virological response (SVR) is very high, but close attention must be paid to the possible occurrence of hepatocellular carcinoma (HCC) and reactivation of hepatitis B virus (HBV) in patients with co-infection who achieved SVR in short term. HCC occurrence was more often observed in patients with previous HCC history. We found occurrence of HCC in 178 (29.6%) of 602 patients with previous HCC history (15.4 months mean follow-up post-DAA initiation) but, in contrast, in only 604 (1.3%) of 45,870 patients without previous HCC history (18.2 months mean follow-up). Thus, in these guidelines, we recommend the following: in patients with previous HCC history, surveillance at 4-month intervals for HCC by ultrasonography (US) and tumor markers should be performed. In patients without previous HCC history, surveillance at 6- to 12-month intervals for HCC including US is recommended until the long-term DAA treatment effects, especially for the resolution of liver fibrosis, are confirmed. This guideline also includes recommendations on how to follow-up patients who have been infected with both HCV and HBV. When HCV was eradicated in these HBsAg-positive patients or patients with previous HBV infection (anti-HBc and/or anti-HBs-positive), it was shown that HBV reactivation or HBV DNA reappearance was observed in 67 (41.4%) of 162 or 12 (0.9%) of 1317, respectively. For these co-infected patients, careful attention should be paid to HBV reactivation for 24 weeks post-treatment.